Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis.

MLA

McQuade, Jennifer L., et al. “Association of Body-Mass Index and Outcomes in Patients with Metastatic Melanoma Treated with Targeted Therapy, Immunotherapy, or Chemotherapy: A Retrospective, Multicohort Analysis.” The Lancet. Oncology, vol. 19, no. 3, Mar. 2018, pp. 310–22. EBSCOhost, https://doi.org/10.1016/S1470-2045(18)30078-0.

APA

McQuade, J. L., Daniel, C. R., Hess, K. R., Mak, C., Wang, D. Y., Rai, R. R., Park, J. J., Haydu, L. E., Spencer, C., Wongchenko, M., Lane, S., Lee, D.-Y., Kaper, M., McKean, M., Beckermann, K. E., Rubinstein, S. M., Rooney, I., Musib, L., Budha, N., … Davies, M. A. (2018). Association of body-mass index and outcomes in patients with metastatic melanoma treated with targeted therapy, immunotherapy, or chemotherapy: a retrospective, multicohort analysis. The Lancet. Oncology, 19(3), 310–322. https://doi.org/10.1016/S1470-2045(18)30078-0

Chicago

McQuade, Jennifer L, Carrie R Daniel, Kenneth R Hess, Carmen Mak, Daniel Y Wang, Rajat R Rai, John J Park, et al. 2018. “Association of Body-Mass Index and Outcomes in Patients with Metastatic Melanoma Treated with Targeted Therapy, Immunotherapy, or Chemotherapy: A Retrospective, Multicohort Analysis.” The Lancet. Oncology 19 (3): 310–22. doi:10.1016/S1470-2045(18)30078-0.